Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 85
Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics ACRONYMS ASCO American Society of Clinical Oncology ASR Analyte-Specific Reagent CAP College of American Pathologists CMS Centers for Medicare & Medicaid Services CLIA Clinical Laboratory Improvement Amendment CPT Current Procedural Terminology EGAPP Evaluation of Genomic Applications in Practice and Prevention EGF Epidermal Growth Factor EGFR Epidermal Growth Factor Receptor FDA Food and Drug Administration FISH Fluorescent In Situ Hybridization HER2 Human Epidermal Growth Factor Receptor 2 HIPAA Health Insurance Portability and Accountability Act IHC Immunohistochemistry IVD In Vitro Diagnostic LOH Loss of Heterozygosity mRNA Messenger Ribonucleic Acid MIAME Minimum Information About a Microarray Experiment NBN National Biospecimen Network NCCN National Comprehensive Cancer Network NCI National Cancer Institute NICE National Institute for Health and Clinical Excellence (of the United Kingdom) NIH National Institutes of Health (of the United States) PET Positron Emission Tomography PMA Premarket Approval PSA Prostate-Specific Antigen QALY Quality-Adjusted Life-Year SNP Single Nucleotide Polymorphism SOP Standard Operating Procedure SPORE Specialized Programs of Research Excellence TEC Technology Evaluation Center (of BlueCross BlueShield) USPSTF United States Preventive Services Task Force
Representative terms from entire chapter: